Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481142 | 0.90 | MTNR1A (0.47) | MTNR1AMTNR1BHDAC1NPC1RAB9A | |
| SCHEMBL6481831 | 0.89 | GAA (0.40) | MTNR1ACA1CA2CA7CA14 | |
| SCHEMBL6475845 | 0.87 | GRIA4 (0.41) | MTNR1AMTNR1BCA1CA2GRIA4 | |
| SCHEMBL6475441 | 0.85 | GRIA4 (0.42) | ERCC1ERCC4RECQLMTNR1AMTNR1B | |
| SCHEMBL6482324 | 0.85 | GRIA4 (0.46) | MTNR1AMTNR1BCA2GRIA4 | |
| SCHEMBL6480684 | 0.84 | CA1 (0.41) | RECQLMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL6480391 | 0.84 | TP53 (0.40) | RECQLMTNR1AMTNR1BNPC1RAB9A | |
| SCHEMBL6766022 | 0.84 | TP53 (0.41) | MTNR1AMTNR1BGRIA4 | |
| SCHEMBL6482281 | 0.82 | ACACB (0.50) | MTNR1AMTNR1B | |
| SCHEMBL6473902 | 0.81 | GRIA4 (0.41) | CA1CA2NPC1RAB9AGRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | claimed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1265857-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001068592-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225266-A1 | Sulfonamide derivatives | GRIN2A, GRM2, GRIA2 | ERCC1 4671/4885ERCC4 4707/4885RECQL 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.